CA2556219A1 - Methodes de dosage cellulaire par controle de l'impedance du substrat cellulaire - Google Patents
Methodes de dosage cellulaire par controle de l'impedance du substrat cellulaire Download PDFInfo
- Publication number
- CA2556219A1 CA2556219A1 CA002556219A CA2556219A CA2556219A1 CA 2556219 A1 CA2556219 A1 CA 2556219A1 CA 002556219 A CA002556219 A CA 002556219A CA 2556219 A CA2556219 A CA 2556219A CA 2556219 A1 CA2556219 A1 CA 2556219A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cells
- test compound
- impedance
- well
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 249
- 239000000758 substrate Substances 0.000 title claims abstract description 243
- 238000012544 monitoring process Methods 0.000 title claims abstract description 195
- 150000001875 compounds Chemical class 0.000 claims abstract description 689
- 238000012360 testing method Methods 0.000 claims abstract description 367
- 238000003491 array Methods 0.000 claims abstract description 162
- 230000000694 effects Effects 0.000 claims abstract description 91
- 230000003013 cytotoxicity Effects 0.000 claims abstract description 55
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract description 55
- 210000004027 cell Anatomy 0.000 claims description 1641
- 238000003556 assay Methods 0.000 claims description 177
- 230000008859 change Effects 0.000 claims description 153
- 239000012530 fluid Substances 0.000 claims description 120
- 238000002847 impedance measurement Methods 0.000 claims description 117
- 230000004044 response Effects 0.000 claims description 102
- 230000012010 growth Effects 0.000 claims description 88
- 230000036962 time dependent Effects 0.000 claims description 85
- 230000010261 cell growth Effects 0.000 claims description 50
- 230000004663 cell proliferation Effects 0.000 claims description 45
- 230000036755 cellular response Effects 0.000 claims description 44
- 230000001404 mediated effect Effects 0.000 claims description 44
- 230000006907 apoptotic process Effects 0.000 claims description 38
- 238000009739 binding Methods 0.000 claims description 34
- 230000027455 binding Effects 0.000 claims description 31
- 238000011002 quantification Methods 0.000 claims description 29
- 210000002325 somatostatin-secreting cell Anatomy 0.000 claims description 29
- 230000001788 irregular Effects 0.000 claims description 27
- 231100000433 cytotoxic Toxicity 0.000 claims description 26
- 230000001472 cytotoxic effect Effects 0.000 claims description 26
- 238000001514 detection method Methods 0.000 claims description 24
- 230000002900 effect on cell Effects 0.000 claims description 24
- 210000004292 cytoskeleton Anatomy 0.000 claims description 22
- 230000017074 necrotic cell death Effects 0.000 claims description 20
- 230000030833 cell death Effects 0.000 claims description 19
- 230000006870 function Effects 0.000 claims description 19
- 230000000638 stimulation Effects 0.000 claims description 19
- 230000021164 cell adhesion Effects 0.000 claims description 18
- 230000022131 cell cycle Effects 0.000 claims description 18
- 230000010534 mechanism of action Effects 0.000 claims description 18
- 230000020411 cell activation Effects 0.000 claims description 16
- 230000024245 cell differentiation Effects 0.000 claims description 16
- 238000003908 quality control method Methods 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 230000003833 cell viability Effects 0.000 claims description 15
- 230000003472 neutralizing effect Effects 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 14
- 230000036285 pathological change Effects 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 231100000673 dose–response relationship Toxicity 0.000 claims description 13
- 230000008520 organization Effects 0.000 claims description 12
- 239000000688 bacterial toxin Substances 0.000 claims description 11
- 230000001351 cycling effect Effects 0.000 claims description 8
- 230000003436 cytoskeletal effect Effects 0.000 claims description 7
- 230000032823 cell division Effects 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 238000009826 distribution Methods 0.000 claims description 6
- 230000004543 DNA replication Effects 0.000 claims description 4
- 230000006369 cell cycle progression Effects 0.000 claims description 4
- 101000966429 Chlamydomonas reinhardtii Dynein, 70 kDa intermediate chain, flagellar outer arm Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- 108010017842 Telomerase Proteins 0.000 claims 3
- 101710183280 Topoisomerase Proteins 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 230000022983 regulation of cell cycle Effects 0.000 claims 3
- 230000035897 transcription Effects 0.000 claims 3
- 238000013518 transcription Methods 0.000 claims 3
- 238000013519 translation Methods 0.000 claims 3
- 230000014616 translation Effects 0.000 claims 3
- 238000000423 cell based assay Methods 0.000 abstract description 41
- 238000012806 monitoring device Methods 0.000 abstract description 24
- 238000002784 cytotoxicity assay Methods 0.000 abstract description 10
- 231100000263 cytotoxicity test Toxicity 0.000 abstract description 10
- 238000005259 measurement Methods 0.000 description 41
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 36
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 30
- 229930012538 Paclitaxel Natural products 0.000 description 29
- 229960001592 paclitaxel Drugs 0.000 description 29
- 239000003814 drug Substances 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 24
- 239000000725 suspension Substances 0.000 description 21
- 230000007246 mechanism Effects 0.000 description 20
- 230000006399 behavior Effects 0.000 description 18
- 229960004679 doxorubicin Drugs 0.000 description 18
- 238000004364 calculation method Methods 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 230000007402 cytotoxic response Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 230000007480 spreading Effects 0.000 description 14
- 238000003892 spreading Methods 0.000 description 14
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 14
- 102400001368 Epidermal growth factor Human genes 0.000 description 13
- 101800003838 Epidermal growth factor Proteins 0.000 description 13
- 229940116977 epidermal growth factor Drugs 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- 238000010899 nucleation Methods 0.000 description 13
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 230000003698 anagen phase Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 239000006285 cell suspension Substances 0.000 description 11
- 238000013461 design Methods 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000012088 reference solution Substances 0.000 description 11
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- 238000001516 cell proliferation assay Methods 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 206010013710 Drug interaction Diseases 0.000 description 9
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 229960003048 vinblastine Drugs 0.000 description 9
- 102000016359 Fibronectins Human genes 0.000 description 8
- 108010067306 Fibronectins Proteins 0.000 description 8
- 238000000134 MTT assay Methods 0.000 description 8
- 231100000002 MTT assay Toxicity 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 238000009795 derivation Methods 0.000 description 8
- 239000010408 film Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000004962 physiological condition Effects 0.000 description 8
- 238000007747 plating Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 5
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000025084 cell cycle arrest Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 5
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- -1 urine Substances 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000002508 compound effect Effects 0.000 description 4
- 230000005684 electric field Effects 0.000 description 4
- 231100000317 environmental toxin Toxicity 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010009711 Phalloidine Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000003352 cell adhesion assay Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000009149 molecular binding Effects 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
- 229960001225 rifampicin Drugs 0.000 description 3
- 230000022932 ruffle assembly Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000010822 cell death assay Methods 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000011152 fibreglass Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 235000003869 genetically modified organism Nutrition 0.000 description 2
- 238000009650 gentamicin protection assay Methods 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 238000000670 ligand binding assay Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 239000000007 protein synthesis inhibitor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000002924 silencing RNA Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 238000004870 electrical engineering Methods 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 238000003366 endpoint assay Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000001453 impedance spectrum Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000005355 lead glass Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000005919 time-dependent effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
- G01N33/4836—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures using multielectrode arrays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/06—Plates; Walls; Drawers; Multilayer plates
- C12M25/08—Plates; Walls; Drawers; Multilayer plates electrically charged
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
- C12M41/36—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of biomass, e.g. colony counters or by turbidity measurements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/021—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance before and after chemical transformation of the material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Sustainable Development (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54292704P | 2004-02-09 | 2004-02-09 | |
| US60/542,927 | 2004-02-09 | ||
| US54871304P | 2004-02-27 | 2004-02-27 | |
| US60/548,713 | 2004-02-27 | ||
| US61460104P | 2004-09-29 | 2004-09-29 | |
| US60/614,601 | 2004-09-29 | ||
| US10/987,732 US7192752B2 (en) | 2002-12-20 | 2004-11-12 | Real time electronic cell sensing systems and applications for cell-based assays |
| US10/987,732 | 2004-11-12 | ||
| PCT/US2005/004481 WO2005077104A2 (fr) | 2004-02-09 | 2005-02-09 | Systemes de detection de cellules electroniques en temps reel et applications en matiere de profilage de cytotoxicite et dosages de composes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2556219A1 true CA2556219A1 (fr) | 2005-08-25 |
Family
ID=40518464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002556219A Abandoned CA2556219A1 (fr) | 2004-02-09 | 2005-02-09 | Methodes de dosage cellulaire par controle de l'impedance du substrat cellulaire |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1749203A4 (fr) |
| CN (1) | CN101400780B (fr) |
| CA (1) | CA2556219A1 (fr) |
| WO (1) | WO2005077104A2 (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560269B2 (en) | 2002-12-20 | 2009-07-14 | Acea Biosciences, Inc. | Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays |
| US7192752B2 (en) | 2002-12-20 | 2007-03-20 | Acea Biosciences | Real time electronic cell sensing systems and applications for cell-based assays |
| US8263375B2 (en) | 2002-12-20 | 2012-09-11 | Acea Biosciences | Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology |
| US11346797B2 (en) | 2002-12-20 | 2022-05-31 | Agilent Technologies, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties |
| US10551371B2 (en) | 2003-11-10 | 2020-02-04 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function |
| US10539523B2 (en) | 2002-12-20 | 2020-01-21 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties |
| US10215748B2 (en) | 2002-12-20 | 2019-02-26 | Acea Biosciences, Inc. | Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways |
| WO2006015387A2 (fr) | 2004-08-04 | 2006-02-09 | Xiao Xu | Procede de dosage de la destruction de cellules cibles par des cellules tueuses naturelles, des lymphocytes t cytotoxiques et des neutrophiles, a l'aide de la technique de detection micro-electronique de cellules en temps reel |
| DE602007008357D1 (de) | 2006-01-04 | 2010-09-23 | Novartis Ag | Antikörperabhängiger zellulärer zytotoxizitätstest |
| EP2064644A4 (fr) * | 2006-09-20 | 2010-12-29 | Acea Biosciences Inc | Utilisation du profilage cytologique base sur l'impedance pour classer des profils de reponses cellulaires lors d'une exposition a des agents biologiquement actifs |
| EP2103933B1 (fr) | 2008-02-25 | 2011-07-27 | Universität Leipzig | Dispositif et procédé de mesure d'impédance dans des tissus organotypiques |
| EP2291645B1 (fr) | 2008-05-05 | 2015-09-09 | Acea Biosciences, Inc. | Surveillance sans marqueur d'un couplage excitation-contraction et cellules pouvant être excitées utilisant des systèmes fondés sur l'impédance avec une résolution dans le temps de l'ordre de la milliseconde |
| US8771202B2 (en) | 2010-01-19 | 2014-07-08 | Becton Dickinson And Company | Electrode layout for blood test sensor strip |
| WO2011146531A1 (fr) | 2010-05-18 | 2011-11-24 | Acea Biosciences, Inc | Analyse de données de signaux de battements de cardiomyocytes à base d'impédance tels que détectés sur des instruments cardiologiques d'analyse de cellules en temps réel (rtca) |
| CN103675031B (zh) * | 2013-12-18 | 2015-09-02 | 江苏大学 | 一种高通量细胞毒性检测方法 |
| EP3035052A1 (fr) | 2014-12-18 | 2016-06-22 | Helmholtz-Zentrum für Infektionsforschung GmbH | Procédé et dispositif de mesure pour la détermination de la vitesse de croissance d'un biofilm |
| US12066428B2 (en) | 2015-11-20 | 2024-08-20 | Agilent Technologies, Inc. | Cell-substrate impedance monitoring of cancer cells |
| WO2017087945A1 (fr) * | 2015-11-20 | 2017-05-26 | Acea Biosciences, Inc. | Surveillance de l'impédance de substrat cellulaire de cellules cancéreuses |
| CN110582569B (zh) | 2017-03-03 | 2024-04-02 | 安捷伦科技有限公司 | 用于iPSC和ESC衍生的心肌细胞的功能成熟的方法和系统 |
| WO2019028122A1 (fr) * | 2017-08-01 | 2019-02-07 | Acea Biosciences, Inc. | Surveillance d'impédance de substrat cellulaire de cellules cancéreuses de lignée, d'origine ou de stade différents |
| RO133794A2 (ro) * | 2018-06-13 | 2019-12-30 | Centrul Internaţional De Biodinamică | Metodă şi dispozitiv de detecţie a unor compuşi bioactivi, de ex. citotoxici, utilizând senzori cu celule stimulate |
| US11733323B2 (en) | 2018-06-13 | 2023-08-22 | Centrul International De Biodinamica | Systems and methods for measuring cellular response to target analytes by controlled application of an oscillating stimulus |
| CN111751522B (zh) * | 2019-03-27 | 2023-06-20 | 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 | 一种细胞检测分析仪及细胞增殖信息的检测方法 |
| CN110568037B (zh) * | 2019-09-02 | 2021-12-03 | 江南大学 | 用于啶虫脒和吡虫啉联合毒性评价的电化学细胞传感器的构建方法及其应用 |
| US20210301245A1 (en) | 2020-03-29 | 2021-09-30 | Agilent Technologies, Inc. | Systems and methods for electronically and optically monitoring biological samples |
| CN111735752A (zh) * | 2020-07-01 | 2020-10-02 | 京东方科技集团股份有限公司 | 细胞检测装置和细胞检测系统 |
| CN112485301B (zh) * | 2020-11-25 | 2023-07-14 | 三诺生物传感股份有限公司 | 一种电化学测试装置的测试方法、系统、设备及介质 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3890201A (en) * | 1974-09-26 | 1975-06-17 | Bactomatic Inc | Multi-chamber impedance measuring module-cap combination |
| US4067951A (en) * | 1975-11-19 | 1978-01-10 | Bactomatic Inc. | Process for making impedance measuring module |
| US5187096A (en) * | 1991-08-08 | 1993-02-16 | Rensselaer Polytechnic Institute | Cell substrate electrical impedance sensor with multiple electrode array |
| JPH11187865A (ja) * | 1997-12-25 | 1999-07-13 | Matsushita Electric Ind Co Ltd | 細胞電位測定電極及びこれを用いた測定装置 |
| US6477479B1 (en) * | 1998-12-11 | 2002-11-05 | Symyx Technologies | Sensor array for rapid materials characterization |
| JP4861584B2 (ja) * | 1999-10-01 | 2012-01-25 | ソフィオン・バイオサイエンス・アクティーゼルスカブ | イオンチャネルの電気生理的性質を測定及び／または監視するための基体及び方法 |
| TWI245895B (en) * | 2001-11-29 | 2005-12-21 | Sun-Wing Tong | Molecular detection and assay by electrobiochip micro-array |
| AU2003269911A1 (en) * | 2002-07-20 | 2004-02-09 | Acea Biosciences, Inc. | Impedance based apparatuses and methods for analyzing cells and particles |
| US7192752B2 (en) * | 2002-12-20 | 2007-03-20 | Acea Biosciences | Real time electronic cell sensing systems and applications for cell-based assays |
-
2005
- 2005-02-09 CN CN2005800122559A patent/CN101400780B/zh active Active
- 2005-02-09 EP EP05722991A patent/EP1749203A4/fr not_active Withdrawn
- 2005-02-09 CA CA002556219A patent/CA2556219A1/fr not_active Abandoned
- 2005-02-09 WO PCT/US2005/004481 patent/WO2005077104A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP1749203A2 (fr) | 2007-02-07 |
| CN101400780A (zh) | 2009-04-01 |
| EP1749203A4 (fr) | 2009-05-06 |
| WO2005077104A3 (fr) | 2008-08-14 |
| WO2005077104A2 (fr) | 2005-08-25 |
| CN101400780B (zh) | 2012-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9399787B2 (en) | Real-time electronic cell sensing system and applications for cytotoxicity profiling and compound assays | |
| CA2556219A1 (fr) | Methodes de dosage cellulaire par controle de l'impedance du substrat cellulaire | |
| US10725023B2 (en) | Method of measuring cell-substrate impedance in living cells to identify compounds affecting receptor tyrosine kinase (RTK) activity and pathways for the treatment of cancer | |
| US11604197B2 (en) | Real time electronic cell sensing systems and applications for cell-based assays | |
| EP1773979B1 (fr) | Controle dynamique de l'activation de la proteine g (gpcr) dans des cellules vivantes mettant en oeuvre la technologie de detection micro-electronique de cellules en temps reel | |
| US7468255B2 (en) | Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology | |
| US7732127B2 (en) | Dynamic monitoring of cell adhesion and spreading using the RT-CES system | |
| EP2450698B1 (fr) | Système de détection de cellule électronique en temps réel et application pour le profilage de la cytotoxicité et l'analyse de composés | |
| EP1800312A2 (fr) | Surveillance dynamique de l'adhesion et de la diffusion cellulaire a l'aide du systeme rt-ces | |
| US20230145666A1 (en) | Real time electronic cell sensing systems and applications for cell-based assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20140304 |